Use of topical corticosteroids in children with eczema does not have negative side effects
A new study published in the journal Pediatric Dermatology reveals that routine, long-term use of topical corticosteroids (TCS) for treating children with eczema does not cause any significant, negative side effects.
Parental phobia of TCS is widespread and leads to poorly managed eczema in children. The commonest fear is that TCS use will "thin the skin." Parents fears are also shared by many health care providers, including pharmacists.
Led by Gayle Fischer, MBBS, FACD, of The University of Sydney, researchers studied 92 children, 70 of which were part of the study/dermatitis group while the other 22 were categorized in a control group. Researchers convinced the parents of these 70 children to use enough TCS to control their children's eczema very well so that they were virtually free of eczema consistently. The 22 children in the control group were not using TCS.
Researchers then evaluated the children by examining them for any signs of skin thinning and by also examining their treated and untreated skin by dermoscopy, a technique which utilizes a mini-microscope to search for even the most subtle signs of TCS side effects.
They found that the children using TCS had no evidence of skin thinning even though they were using enough TCS to produce complete control of their eczema. These children were no different to the children who were not using TCS at all.
"Our results show that normal routine use of TCS does not cause skin thinning, and parents should be reassured. We hope that our work will give them the confidence to use TCS safely and effectively" Fischer notes.
Provided by
Wiley
-
Dog ownership is associated with reduced eczema in children with dog allergies
Sep 30, 2010 |
not rated yet |
0
-
India's TCS quarterly profit jumps 21 percent
Jul 15, 2010 |
not rated yet |
0
-
India software giant TCS profits up 30%
Jan 17, 2011 |
not rated yet |
0
-
India's TCS announces 29 pct quarterly profit jump
Oct 16, 2009 |
not rated yet |
0
-
Probiotic bacteria don't make eczema better -- and may have side effects
Oct 08, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
2 hours ago
-
If you became brain-dead, would you want them to pull the plug?
19 hours ago
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Acne pill benefits outweigh blood clot risk: EU agency
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications
19 hours ago |
not rated yet |
0
First influenza vaccine brought to clinical testing
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications
20 hours ago |
not rated yet |
0
Aspirin not always best treatment for many individuals
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications
May 16, 2013 |
3.5 / 5 (2) |
0
|
FDA: lower ambien's dose to prevent drowsy driving
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications
May 15, 2013 |
not rated yet |
0
Simponi approved for ulcerative colitis
(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.
Medications
May 15, 2013 |
not rated yet |
0
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
Melon focus headband turns to Kickstarter for rollout plans
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Temporal processing in the olfactory system
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
Individuals who drink heavily and smoke may show 'early aging' of the brain
Treatment for alcohol use disorders works best if the patient actively understands and incorporates the interventions provided in the clinic. Multiple factors can influence both the type and degree of neurocognitive abnormalities ...